Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Alterations in DNA methylation profiles in cancellous bone of postmenopausal women with osteoporosis

Zhou Y., Yang L., Wang H., Chen X., Jiang W., Wang Z.

Prospective Study on Osteoarthritis, published in FEBS Open Bio (2020) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
FEBS Open Bio (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32496000
PMCID
PMC7396431
DOI
10.1002/2211-5463.12907
Citations
18

Abstract (original English)

Osteoporosis is characterized by systemic microarchitecture impairment and bone loss, which ultimately lead to fragility fractures. This disease is most common in older people, especially in postmenopausal women. Cancellous bone is affected by osteoporosis earlier than cortical bone, and DNA methylation microarray analysis of the hip cancellous bone of patients with osteoarthritis revealed differential methylation. In view of the important role of cancellous bone in bone development, we examined genome-wide DNA methylation profiles in the cancellous bone from patients with postmenopausal osteoporosis versus healthy postmenopausal women using Illumina 850K methylation microarray analysis. Under a threshold of P 0.2, a total of 17 and 34 key differentially methylated genes were further identified at the promoter region and cytosine- phosphate- guanine (CpG) islands (such as PRKCZ, GNA11 and COL4A1), respectively. PLEKHA2, PLEKHB1, PNPLA7, SCD, MGST3 and TSNAX were the most common differentially methylated genes at both the promoter region and CpG islands. Five important signaling pathways, including the calcium signaling pathway, the cyclic guanosine phospho-protein kinase G (cGMP-PKG) signaling pathway, endocytosis, the Rap1 signaling pathway and the AMPK signaling pathway were identified. Our study may be suitable as a basis for exploring the mechanisms underlying osteoporosis

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansOsteoporosisDNA MethylationPostmenopauseAgedAged, 80 and overMiddle AgedFemaleCancellous Bone

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research